Pharmaceutical Product Development Inc. (PPDI) said it reached an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome and the other to treat complicated skin and skin structure and respiratory infections.
Under two agreements, PPD in-licensed the two assets and would advance the compounds through Phase II development. At the completion of Phase II, Janssen would have the option to resume development and commercialization of each compound. In exchange, PPD would receive up to $330 million in clinical and sales milestones and royalties on sales of the compounds if approved for marketing. If Janssen does not buy back a program, PPD would have the option to continue developing and commercializing the compound for that program; and Janssen would receive up to $250 million USD in clinical and sales milestones and royalties on sales of the compounds if approved for marketing.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.